To hear about similar clinical trials, please enter your email below
Trial Title:
Chronic Kidney Disease Patient in Chronic Myloied Leukemia
NCT ID:
NCT06266975
Condition:
Chronic Myeloid Leukemia in Remission
Conditions: Official terms:
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kidney Diseases
Renal Insufficiency, Chronic
Tyrosine Kinase Inhibitors
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Device
Intervention name:
Biobsy from kidney
Description:
using tyrosine kinase inhibitors particulary imatinib in ttt CML patients
Other name:
drug , tyrosine kinase inhibitors particulary imatinib in ttt CML patients
Summary:
To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic
myeloid leukemia .
Detailed description:
- Chronic myeloid leukemia (CML) is a cancer of bone marrow that leads to an increased
number of white blood cells. CML is more prevalent in the elderly and is
characterized by weight loss, tiredness, shortness of breath, excessive sweating,
bone pain, and frequent infections. [1] According to the American Cancer Society's
estimates, CML represents 15% of all new leukemia cases.[2] The global burden of
disease (GBD) study 2015 revealed that leukemia was under the top ten leading causes
of death globally.[3] However, the latest GBD study found a decrease in the
age-standardized incidence rate and the death rate from 1990-2017.[4] This dramatic
improvement in the overall survival and health-related quality of life among CML
patients was attributed to the impact of new therapeutic strategies. Tyrosine kinase
inhibitors (TKIs), particularly imatinib, emerged as a potential therapeutic agent
for the treatment of CML, reducing epidemiological burden (incidence rate), and
improve quality of life.[5]
- The definition and classification of chronic kidney disease (CKD) have evolved over
time, but current international guidelines define this condition as decreased kidney
function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1•73
m2, or markers of kidney damage, or both, of at least 3 months duration, regardless
of the underlying cause[6] Diagnosis is commonly made after chance findings from
screening tests (urinary dipstick or blood tests), or when symptoms become severe.
The best available indicator of overall kidney function is GFR, which is measured
either via exogenous markers (eg, DTPA, iohexol), or estimated using equations.
Presence of proteinuria is associated with increased risk of progression of CKD and
death. Presence of proteinuria is associated with increased risk of progression of
CKD and death.[7,8] Kidney biopsy samples can show definitive evidence of CKD,
through common changes such as glomerular sclerosis, tubular atrophy, and
interstitial fibrosis. Complications include anaemia due to reduced production of
erythropoietin by the kidney; reduced red blood cell survival and iron deficiency;
and mineral bone disease caused by disturbed vitamin D, calcium, and phosphate
metabolism.[9
Criteria for eligibility:
Study pop:
all sexes , adult , not diabetic , not known CKD before diagnosed of CML
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:1_ Chronic myloid leukemia patiants who diagonised by biopsy , 2_ CBC.
- Exclusion : 1_pts known to have CKD before diagnosed of CML. 2- known Diabetic pts
3-imaging suggestive CKD etiology rather than CML effect eg.PKD,renal stones,chronic
pyelonephritis
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Start date:
February 2024
Completion date:
November 2026
Lead sponsor:
Agency:
Sahar Mohammed Gad
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06266975
